{"protocolSection":{"identificationModule":{"nctId":"NCT06471348","orgStudyIdInfo":{"id":"IRB-P00048597"},"organization":{"fullName":"Boston Children's Hospital","class":"OTHER"},"briefTitle":"Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine With Epinephrine","officialTitle":"Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-15","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-08-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-08-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-05-21","studyFirstSubmitQcDate":"2024-06-18","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-18","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Craig Birch","investigatorTitle":"Instructor of Orthopedic Surgery, Harvard Medical School","investigatorAffiliation":"Boston Children's Hospital"},"leadSponsor":{"name":"Boston Children's Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A randomized controlled trial (RCT) investigating whether the local anesthetic injection of liposomal bupivacaine during posterior spinal fusion (PSF) for AIS is more effective in reducing acute postoperative opioid consumption compared to an equal volume injection of 0.25% bupivacaine with epinephrine for patients aged 10 to 17, with 128 patients randomly assigned to one of two arms: liposomal bupivacaine or 0.25% bupivacaine with epinephrine."},"conditionsModule":{"conditions":["Post Operative Pain","Spinal Fusion"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":128,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Local infiltration with liposomal bupivacaine","type":"EXPERIMENTAL","description":"Patients randomized into the liposomal bupivacaine group will receive anesthesia and undergo standard posterior spinal fusion surgery. The local infiltration would occur in a single stage, after instrumentation and correction maneuver is performed, just prior to closure of the deep fascial layer. The dose would be injected via multiple small volume injections into the paraspinal musculature, spaced approximately 1 cm apart.","interventionNames":["Drug: Bupivacaine liposome injectable suspension"]},{"label":"Local infiltration with 0.25% bupivacaine with epinephrine","type":"ACTIVE_COMPARATOR","description":"Patients randomized into the 0.25% bupivacaine with epinephrine group will receive anesthesia and undergo standard posterior spinal fusion surgery under the same condition as the intervention group with one exception: the local infiltration will be made up of equal volume of 0.25% bupivacaine with epinephrine. The equal volume of 0.25% bupivacaine with epinephrine will be used in the exact same administration technique as the liposomal bupivacaine group, involving multiple small-volume injections to the paraspinal musculature spaced approximately 1 centimeter apart.","interventionNames":["Drug: Bupivacaine Hydrochloride and Epinephrine Injection"]}],"interventions":[{"type":"DRUG","name":"Bupivacaine liposome injectable suspension","description":"EXPAREL is a milky white too off-white aqueous suspension available as single-dose vials. Each mL contains 13.3 mg of bupivacaine, which is contained in multivesicular liposomes.","armGroupLabels":["Local infiltration with liposomal bupivacaine"],"otherNames":["EXPAREL"]},{"type":"DRUG","name":"Bupivacaine Hydrochloride and Epinephrine Injection","description":"Sensorcaine-MPF with Epinephrine 1:200,000 is a clear, colorless to slightly yellow solution available as single-dose vials. Each mL contains bupivacaine hydrochloride, 0.005 mg epinephrine, and 0.5 mg sodium metabisulfite (antioxidant), and 0.2 mg anhydrous citric acid (stabilizer).","armGroupLabels":["Local infiltration with 0.25% bupivacaine with epinephrine"],"otherNames":["Sensorcaine-MPF with Epinephrine 1:200,000"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Total amount of morphine equivalents per kilogram","description":"Total amount of morphine equivalents per kilogram during the first 72 hours postoperatively.","timeFrame":"72 hours postoperatively"}],"secondaryOutcomes":[{"measure":"Numeric Rating Scale (NRS) pain scores","description":"The average Numeric Rating Scale pain score (on a scale of 0-10) during the first 72 hours postoperatively will be computed from at most six values typically obtained every four to six hours following surgery. The higher the score, the higher the experienced pain of the individual.","timeFrame":"72 hours postoperatively"},{"measure":"Pain, functional ability, and mental health scores","description":"SRS-22r scores at 1-, 6-, 12-, and 24-months post-operatively. The Scoliosis Patient Questionnaire Version 22r (SRS-22r) is a patient-reported outcome instrument with 22 questions that evaluates the impact of scoliosis and surgery on patient quality of life. Scores from the SRS-22r are compiled into five domain scores: function, pain, self-image, mental health, and satisfaction with management of scoliosis. Each domain score is reported on a scale form 1-5. The lower the score, the worse the outcome.","timeFrame":"1-, 6-, 12-, and 24-months postoperatively"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥10 years old and ≤17 years old at assessment\n* Diagnosis of Adolescent Idiopathic Scoliosis\n* Planned surgical treatment of progressive spinal deformity with posterior spinal fusion\n\nExclusion Criteria:\n\n* Diagnosis of neuromuscular, syndromic, or congenital scoliosis\n* History of known allergy to local anesthesia\n* Chronic pre-operative opioid consumptions\n* Any other analgesic treatment for chronic pain before surgery\n* Psychiatric or neurological disorders\n* Cannot fluently read or speak English","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"centralContacts":[{"name":"Sydney Lee, BA","role":"CONTACT","phone":"617-919-1764","phoneExt":"41764","email":"Sydney.Lee@childrens.harvard.edu"},{"name":"Mikayla Flowers, MA","role":"CONTACT","email":"Mikayla.Flowers@childrens.harvard.edu"}],"overallOfficials":[{"name":"Craig Birch, MD","affiliation":"Boston Children's Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Boston Children's Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","contacts":[{"name":"Sydney Lee, BA","role":"CONTACT","phone":"617-919-1764","phoneExt":"41764","email":"Sydney.Lee@childrens.harvard.edu"},{"name":"Craig Birch, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Daniel Hedequist, MD","role":"SUB_INVESTIGATOR"},{"name":"Timothy Hresko, MD","role":"SUB_INVESTIGATOR"},{"name":"Grant Hogue, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000010149","term":"Pain, Postoperative"}],"ancestors":[{"id":"D000011183","term":"Postoperative Complications"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000010146","term":"Pain"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M13069","name":"Pain, Postoperative","asFound":"Post Operative Pain","relevance":"HIGH"},{"id":"M13066","name":"Pain","relevance":"LOW"},{"id":"M14065","name":"Postoperative Complications","relevance":"LOW"},{"id":"M12404","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000004837","term":"Epinephrine"},{"id":"D000064705","term":"Racepinephrine"},{"id":"D000002045","term":"Bupivacaine"},{"id":"C000018285","term":"Epinephryl borate"}],"ancestors":[{"id":"D000000779","term":"Anesthetics, Local"},{"id":"D000000777","term":"Anesthetics"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000000316","term":"Adrenergic alpha-Agonists"},{"id":"D000000322","term":"Adrenergic Agonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000318","term":"Adrenergic beta-Agonists"},{"id":"D000001993","term":"Bronchodilator Agents"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018927","term":"Anti-Asthmatic Agents"},{"id":"D000019141","term":"Respiratory System Agents"},{"id":"D000009184","term":"Mydriatics"},{"id":"D000013566","term":"Sympathomimetics"},{"id":"D000014662","term":"Vasoconstrictor Agents"}],"browseLeaves":[{"id":"M21860","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M7992","name":"Epinephrine","asFound":"Foot","relevance":"HIGH"},{"id":"M30371","name":"Racepinephrine","asFound":"Foot","relevance":"HIGH"},{"id":"M211043","name":"Epinephryl borate","asFound":"Foot","relevance":"HIGH"},{"id":"M4107","name":"Anesthetics","relevance":"LOW"},{"id":"M5315","name":"Bupivacaine","asFound":"Type","relevance":"HIGH"},{"id":"M21320","name":"Citric Acid","relevance":"LOW"},{"id":"M1837","name":"Sodium Citrate","relevance":"LOW"},{"id":"M4292","name":"Antioxidants","relevance":"LOW"},{"id":"M210137","name":"Sodium metabisulfite","relevance":"LOW"},{"id":"M4109","name":"Anesthetics, Local","relevance":"LOW"},{"id":"M20746","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3668","name":"Adrenergic alpha-Agonists","relevance":"LOW"},{"id":"M3673","name":"Adrenergic Agonists","relevance":"LOW"},{"id":"M20504","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M3670","name":"Adrenergic beta-Agonists","relevance":"LOW"},{"id":"M5269","name":"Bronchodilator Agents","relevance":"LOW"},{"id":"M20963","name":"Anti-Asthmatic Agents","relevance":"LOW"},{"id":"M21137","name":"Respiratory System Agents","relevance":"LOW"},{"id":"M12139","name":"Mydriatics","relevance":"LOW"},{"id":"M16345","name":"Sympathomimetics","relevance":"LOW"},{"id":"M17409","name":"Vasoconstrictor Agents","relevance":"LOW"},{"id":"T382","name":"Citrate","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaCoAg","name":"Vasoconstrictor Agents"},{"abbrev":"Resp","name":"Respiratory System Agents"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}